Form 4: BrainStorm Cell Therapeutics Executive Equity Grant

EVP & Chief Business Officer Uri Yablonka received an award of 150,000 restricted stock units from BrainStorm Cell Therapeutics.

Summary

• Uri Yablonka, EVP & Chief Business Officer of BrainStorm Cell Therapeutics, was granted 150,000 restricted stock units (RSUs).
• The grant was issued on February 26, 2026.
• The RSUs vest in two equal tranches: 50% on the grant date and 50% on the six-month anniversary of the grant date, contingent on continued employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no material impact on the company's operational outlook.

Positives

• Alignment of executive interests with shareholders through equity-based compensation.

Negatives

• The grant results in potential dilution for existing shareholders.

Risks

• Continued reliance on equity compensation to retain key management personnel.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation.

Management Comments

• No specific management commentary provided in this disclosure.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice for retention and performance alignment, particularly in companies focused on long-term clinical development.

Comparison to Industry Standards

• The vesting schedule of 50% immediate and 50% after six months is relatively aggressive compared to standard multi-year cliff or graded vesting schedules seen in the broader biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new shares upon vesting.

Next Steps

• Vesting of the remaining 50% of the RSU award on August 26, 2026.

Key Dates

Keywords

BrainStorm Cell Therapeutics, BCLI, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units